<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03189381</url>
  </required_header>
  <id_info>
    <org_study_id>IUSCC-0605</org_study_id>
    <nct_id>NCT03189381</nct_id>
  </id_info>
  <brief_title>Pilot Phase 2 Study Whole Brain Radiation Therapy With Simultaneous Integrated Boost for Patients With Brain Metastases</brief_title>
  <official_title>A Pilot Phase 2 Study Evaluating Dose De-escalation in Whole Brain Radiation Therapy With Simultaneous Integrated Boost for Patients With Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a pilot, Phase 2, sequential two-cohort study designed to test two de-escalated&#xD;
      whole brain radiation therapy (WBRT) dose levels and assess their ability to maintain&#xD;
      acceptable in-brain distant control. The WBRT dose would decrease as the study moves forward,&#xD;
      both in terms of absolute value and equivalent dose in 2 Gray fractions (EQD2) (as determined&#xD;
      by the linear quadratic radiobiological model). The absolute value of the simultaneous&#xD;
      integrated boost (SIB) dose will change with each dose level because the number of fractions&#xD;
      delivered will depend on the WBRT dose. As such, the SIB dose will be manipulated such that&#xD;
      the EQD2 will remain essentially equivalent despite the difference in the number of fractions&#xD;
      delivered. This design will ensure that the only variable is the change in WBRT dose.&#xD;
&#xD;
      The concept is that WBRT with SIB would be expected to maximize both local and in-brain&#xD;
      distant control as has already been shown in studies exploring WBRT with SRS boost. However,&#xD;
      by itself WBRT with SIB does not address the concern over neurocognitive outcomes. Therefore,&#xD;
      investigators hypothesize that there is a lower WBRT dose threshold that will maintain&#xD;
      acceptable in-brain distant control, particularly in the setting of a SIB to gross lesions to&#xD;
      maintain treated lesion control. In addition, lower overall brain dose (including lower&#xD;
      hippocampal dose without specific hippocampal avoidance) may potentially improve&#xD;
      neurocognitive function. Investigators are also interested in evaluating treated lesion&#xD;
      control, overall survival, neurocognitive sequelae of therapy, quality of life, performance&#xD;
      status, and adverse effects of therapy. Biomarker identification for potential correlative&#xD;
      circulating tumor DNA and microRNA is an exploratory endpoint to generate data for future&#xD;
      prospective evaluation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective Evaluate two de-escalated whole brain radiation dose levels (in the setting&#xD;
      of simultaneous integrated boost to gross lesions) with respect to in-brain distant control&#xD;
      for brain metastases, defined as an in-brain failure rate outside of the planning target&#xD;
      volume at 6 months of &lt; 20%.&#xD;
&#xD;
      Secondary Objectives&#xD;
&#xD;
        1. Evaluate treated lesion control at 6 months for brain metastases in the setting of a&#xD;
           predetermined total biologically effective SIB dose as determined by radiographic&#xD;
           progression within the planning target volume with fusion and overlay of follow-up MRIs.&#xD;
&#xD;
        2. Evaluate overall survival at 6 months for brain metastases in the setting of WBRT with&#xD;
           SIB.&#xD;
&#xD;
        3. Evaluate changes in neurocognitive function after WBRT with SIB in the following&#xD;
           domains: verbal learning and memory as assessed by the Hopkins Verbal Learning Test -&#xD;
           Revised (HVLT-R).&#xD;
&#xD;
        4. Evaluate changes in health-related quality of life as assessed by the Functional&#xD;
           Assessment of Cancer Therapy with Brain Subscale (FACT-Br) after WBRT-SIB for brain&#xD;
           metastases.&#xD;
&#xD;
        5. Evaluate changes in performance status as assessed by the Karnofsky Performance Status&#xD;
           tool after WBRT-SIB for brain metastases.&#xD;
&#xD;
        6. Evaluate adverse events after WBRT-SIB for brain metastases according to current CTCAE&#xD;
           criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-brain distant failure rate</measure>
    <time_frame>6 months</time_frame>
    <description>An actuarial 6-month rate of new parenchymal lesions seen outside the planning target volume of any lesion that received SIB on any post-treatment MRI (in all 3 planes)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treated lesion control</measure>
    <time_frame>6 months</time_frame>
    <description>An actuarial 6-month rate of any new, recurrent, or progressing (as defined by Response Assessment in Neuro-Oncology Brain Metastases criteria) tumor within the planning target volume on any post-treatment MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>6 months</time_frame>
    <description>An actuarial 6-month rate of patients still alive regardless of disease status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in neurocognitive function</measure>
    <time_frame>6 months</time_frame>
    <description>Total change in score of neurocognitive tests (Hopkins Verbal Learning Test - Revised, Groton Maze, and Two or One Back Test)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in health-related quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>Total change in score of health-related quality of life test (Functional Assessment of Cancer Therapy with Brain Subscale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in performance status</measure>
    <time_frame>6 months</time_frame>
    <description>Total change in performance status score (Karnofsky)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of early and late adverse effects</measure>
    <time_frame>1 year</time_frame>
    <description>Adverse effects will be defined per CTCAE</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard PCI dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low PCI dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Cohort A</intervention_name>
    <description>Cohort A - WBRT dose = 25 Gy, SIB dose = 42 Gy, # of daily fractions = 10, SIB dose in EQD2 = 49.7 Gy</description>
    <arm_group_label>Cohort A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Cohort B</intervention_name>
    <description>Cohort B - WBRT dose = 20 Gy, SIB dose = 40 Gy, # of daily fractions = 8, SIB dose in EQD2 = 50.0 Gy</description>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Age ≥ 18 at time of consent.&#xD;
&#xD;
          2. Ability to provide written informed consent and HIPAA authorization.&#xD;
&#xD;
          3. Pathological diagnosis of any solid tumor histology (from any site in the body).&#xD;
&#xD;
          4. Pathological or clinical (i.e., by imaging) diagnosis of brain metastatic tumor&#xD;
             lesions.&#xD;
&#xD;
          5. Total volume of lesions ≤ 30 cm3.&#xD;
&#xD;
          6. Maximum volume of largest lesion ≤ 5 cm3.&#xD;
&#xD;
             a. This volume limit would be equivalent to a largest diameter of about 2.1 cm,&#xD;
             assuming a perfect sphere.&#xD;
&#xD;
          7. Not a candidate for or eligible for but refused Gamma Knife radiosurgery.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Previous radiation to the brain, including WBRT or brain radiosurgery.&#xD;
&#xD;
          2. Life expectancy &lt; 6 months (as estimated per current ds-GPA).&#xD;
&#xD;
          3. For histologies not included in the ds-GPA publications or otherwise noted online at&#xD;
             brainmetgpa.com, the PI will use either published or validated data, or the PI's best&#xD;
             clinical judgment to determine the patient's expected survival.&#xD;
&#xD;
          4. Inability to comply with treatment per investigator discretion.&#xD;
&#xD;
          5. Inability to complete neurocognitive assessments per investigator discretion.&#xD;
&#xD;
        Of note, tumor lesion number is not an inclusion or exclusion criteria as we are using&#xD;
        volume-based criteria instead.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin R. Shiue, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathy Lauer</last_name>
    <phone>317-962-3172</phone>
    <email>klauer@iuhealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Indiana University Health Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Lauer</last_name>
      <phone>317-962-3172</phone>
      <email>klauer@iuhealth.org</email>
    </contact>
    <investigator>
      <last_name>Kevin R. Shiue, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Lauer</last_name>
      <phone>317-962-3172</phone>
      <email>klauer@iuhealth.org</email>
    </contact>
    <investigator>
      <last_name>Kevin R. Shiue, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Lauer</last_name>
      <phone>317-962-3172</phone>
      <email>klauer@iuhealth.org</email>
    </contact>
    <investigator>
      <last_name>Kevin R. Shiue, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 14, 2017</study_first_submitted>
  <study_first_submitted_qc>June 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2017</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Kevin Shiue, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Whole Brain Radiation</keyword>
  <keyword>Simultaneous Integrated Boost</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

